Log in to save to my catalogue

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Pre...

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Pre...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11567862

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies

About this item

Full title

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies

Publisher

United States: John Wiley and Sons Inc

Journal title

Alzheimer's & dementia, 2024-11, Vol.20 (11), p.7745-7761

Language

English

Formats

Publication information

Publisher

United States: John Wiley and Sons Inc

More information

Scope and Contents

Contents

INTRODUCTION
The Alzheimer's Prevention Initiative (API) Generation Studies evaluated the BACE inhibitor umibecestat for Alzheimer's disease (AD) prevention. The studies were terminated early, and the reversibility of umibecestat's side effects was assessed.
METHODS
Cognitively unimpaired 60‐ to 75‐year‐old apolipoprotein E (APOE) ε4 homoz...

Alternative Titles

Full title

Reversibility of cognitive worsening observed with BACE inhibitor umibecestat in the Alzheimer's Prevention Initiative (API) Generation Studies

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11567862

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11567862

Other Identifiers

ISSN

1552-5260,1552-5279

E-ISSN

1552-5279

DOI

10.1002/alz.14237

How to access this item